Epitope topography of agonist antibodies to the checkpoint inhibitory receptor BTLA
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (United States)
- Eli Lilly and Company, San Diego, CA (United States); Discovery Biology, San Diego, CA (United States)
- Eli Lilly and Company, San Diego, CA (United States)
- Eli Lilly and Company, Indianapolis, IN (United States)
B and T lymphocyte attenuator (BTLA) is an attractive target for a new class of therapeutics that attempt to rebalance the immune system by agonizing checkpoint inhibitory receptors (CIRs). Herpesvirus entry mediator (HVEM) binds BTLA in both trans- and cis-orientations. We report here the development and structural characterization of three humanized BTLA agonist antibodies, 22B3, 25F7, and 23C8. We determined the crystal structures of the antibody-BTLA complexes, showing that these antibodies bind distinct and non-overlapping epitopes of BTLA. While all three antibodies activate BTLA, 22B3 mimics HVEM binding to BTLA and shows the strongest agonistic activity in functional cell assays and in an imiquimod-induced mouse model of psoriasis. 22B3 is also capable of modulating HVEM signaling through the BTLA-HVEM cis-interaction. The data obtained from crystal structures, biochemical assays, and functional studies provide a mechanistic model of HVEM and BTLA organization on the cell surface and informed the discovery of a highly active BTLA agonist.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- National Institutes of Health (NIH); USDOE Office of Science (SC), Basic Energy Sciences (BES). Scientific User Facilities (SUF)
- Grant/Contract Number:
- AC02-05CH11231; AC02-06CH11357
- OSTI ID:
- 2423419
- Journal Information:
- Structure, Journal Name: Structure Journal Issue: 8 Vol. 31; ISSN 0969-2126
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Structural basis for the antibody neutralization of Herpes simplex virus
HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160